[Vandetanib treatment in refractory advanced lung adenocarcinoma patients: five cases and review of literature].
作者： Qiyi Meng , Junfang Tang , Heling Shi , Lili Guo , Zhe Liu
DOI: 10.3779/J.ISSN.1009-3419.2012.02.11
关键词: Chemotherapy 、 Adverse effect 、 Medicine 、 Lung cancer 、 Progression-free survival 、 Rash 、 Gastroenterology 、 Surgery 、 Internal medicine 、 Progressive disease 、 Adenocarcinoma 、 Vandetanib
摘要: Background and objective Vandetanib is a once-daily oral multi-target inhibitor of vascular endothelial growth factor receptor, epidermal rearranged during transfection (RET) tyrosine kinases. The current study aimed to evaluate the effect safety vandetanib administered in refractory advanced lung adenocarcinoma patients. Methods Five patients who accepted chemotherapy Tarceva therapy as first- second-line treatments received (300 mg, oral, once daily). Results effects are stable disease on two (40%) progressive three (60%). With median follow-up 36 months, one patient remained follow-up. progression free survival (PFS) 2 mean overall 22.6 months. adverse events include rash (n=2), skin change paronychia asymptomatic QTc prolongation ST-T (n=1), diarrhea increased transaminase (n=1). Conclusion There were lower incidences severe side with results similar related reviewed articles. DOI: 10.3779/j.issn.1009-3419.2012.02.11
sci-hub.se 参考文章(24)
D Irmer, J O Funk, A Blaukat, EGFR kinase domain mutations - functional impact and relevance for lung cancer therapy. Oncogene. ,vol. 26, pp. 5693- 5701 ,(2007) , 10.1038/SJ.ONC.1210383
Wei-Xiang Qi, Li-Na Tang, Ai-Na He, Zan Shen, Yang Yao, None, The role of vandetanib in the second-line treatment for advanced non-small-cell-lung cancer: a meta-analysis of four randomized controlled trials. Lung. ,vol. 189, pp. 437- 443 ,(2011) , 10.1007/S00408-011-9332-1
Carrie Lee, Mark Socinski, Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: a review of recent clinical trials. Reviews on Recent Clinical Trials. ,vol. 2, pp. 117- 120 ,(2007) , 10.2174/157488707780599401
Katsuyuki Kiura, Kazuhiko Nakagawa, Tetsu Shinkai, Kenji Eguchi, Yuichiro Ohe, Nobuyuki Yamamoto, Masahiro Tsuboi, Soichiro Yokota, Takashi Seto, Haiyi Jiang, Kazuto Nishio, Nagahiro Saijo, Masahiro Fukuoka, A Randomized, Double-Blind, Phase IIa Dose-Finding Study of Vandetanib (ZD6474) in Japanese Patients With Non-Small Cell Lung Cancer Journal of Thoracic Oncology. ,vol. 3, pp. 386- 393 ,(2008) , 10.1097/JTO.0B013E318168D228
Scott Gettinger, Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer. Biologics: Targets & Therapy. ,vol. 4, pp. 237- 243 ,(2010) , 10.2147/BTT.S7223
J.P. van Meerbeeck, D. Fennell, D. Lacombe, J. Welch, C. Gridelli, A.G. Pallis, L. Serfass, R. Dziadziuszko, Targeted therapies in the treatment of advanced/metastatic NSCLC European Journal of Cancer. ,vol. 45, pp. 2473- 2487 ,(2009) , 10.1016/J.EJCA.2009.06.005
Grzegorz Korpanty, Elizabeth Smyth, Laura A Sullivan, Rolf A Brekken, Desmond N Carney, Antiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway Experimental Biology and Medicine. ,vol. 235, pp. 3- 9 ,(2010) , 10.1258/EBM.2009.009191
Tomohide Tamura, Hironobu Minami, Yasuhide Yamada, Noboru Yamamoto, Tatsu Shimoyama, Haruyasu Murakami, Atsushi Horiike, Yasuhito Fujisaka, Tetsu Shinkai, Makoto Tahara, Kenji Kawada, Hiromichi Ebi, Yasutsuna Sasaki, Haiyi Jiang, Nagahiro Saijo, A Phase I Dose-Escalation Study of ZD6474 in Japanese Patients with Solid, Malignant Tumors Journal of Thoracic Oncology. ,vol. 1, pp. 1002- 1009 ,(2006) , 10.1016/S1556-0864(15)31634-8
Scott Gettinger, Targeted therapy in advanced non-small-cell lung cancer. Seminars in Respiratory and Critical Care Medicine. ,vol. 29, pp. 291- 301 ,(2008) , 10.1055/S-2008-1076749
Marissa N. Balak, Yixuan Gong, Gregory J. Riely, Romel Somwar, Allan R. Li, Maureen F. Zakowski, Anne Chiang, Guangli Yang, Ouathek Ouerfelli, Mark G. Kris, Marc Ladanyi, Vincent A. Miller, William Pao, Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors Clinical Cancer Research. ,vol. 12, pp. 6494- 6501 ,(2006) , 10.1158/1078-0432.CCR-06-1570